Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (June 2025)
31 slides from Inspiremd's investor presentation, June 2025
Slide 1: InspireMD Poised to Revolutionize the Carotid Intervention Market
InspireMD Poised to Revolutionize the Carotid Intervention Market Nasdaq: NSPR
Slide 2: Disclaimers
Disclaimers Forward Looking Statement This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. For
Slide 3: Executive Leadership Team
Executive Leadership Team Deep industry experience and subject matter expertise Marvin Slosman Shane Gleason Craig Shore Andrea Tommosoli Chief Executive Officer Chief Commercial Officer Chief Financial Officer Chief Operating Officer • 30+ years medical device • 20+ years cardiovascular medical • 2
Slide 4: Now Approved in the U.S. CGuard Prime Carotid Stent System
Now Approved in the U.S. CGuard® Prime Carotid Stent System Imminent U.S. Commercial Launch, With a Trained and Seasoned Salesforce at the Ready A New Level of Stroke Prevention is Here ▪ With 60,000+ patients treated worldwide, we’re ready to elevate embolic prevention for U.S. physicians and their
Slide 5: Endovascular Revolution Has Arrived
Endovascular Revolution Has Arrived MicroNetTM covered CGuard® stent platform could become the new gold standard CEREBRAL CORONARY THORACIC/ABDOMINAL PERIPHERAL CAROTID ARTERY ANEURYSMS ARTERY DISEASE AORTIC ANEURYSMS ARTERIAL DISEASE DISEASE5 AWAITING CONVERSION TO ENDO 30% Surgical1 23% Surgical2
Slide 6: $8B Global Market Potential
$8B Global Market Potential ~2.8 million People diagnosed with High Grade Carotid CURRENT UNTREATED GLOBAL MARKET Stenosis (HGCS) $8.0 Billion ~400,000 Global procedures (CEA/CAS/TCAR) annually to treat HGCS (1) ~155,000 CURRENT TREATED US Procedures (CEA/CAS/TCAR) GLOBAL MARKET annually $1.3 Billio
Slide 7: Developer of CGuard Prime Carotid Stent Platform
Developer of CGuard® Prime Carotid Stent Platform Dedicated to advancing the prevention of stroke and treatment of carotid artery disease 7
Slide 8: Transforming the Carotid Intervention Market
Transforming the Carotid Intervention Market CGuard®Carotid Stent Platform CMS Coverage Expanded Proprietary MicroNet Technology Standard Risk and Asymptomatic Reimbursement Highly differentiated platform for treatment of Enables stent-first approach to carotid carotid artery disease and stroke prev
Slide 9: A Picture is Worth a Thousand Words
A Picture is Worth a Thousand Words… VS Surgical Endarterectomy 90% occlusion CGuard® Stent Stenting 9
Slide 10: Carotid Stenting (CAS + TCAR) is on the Rise
Carotid Stenting (CAS + TCAR) is on the Rise CE CS ▪ DRG/CPT data by Facility and HCP 30,000 25,000 ▪ Trailing 12 Quarters through Q4 20,000 2024 (one quarter in arrears) 15,000 ▪ ~147K annual carotid intervention 10,000 CAS coverage claims TCAR coverage expansion 5,000 expansion ▪ Represents ~90% o
Slide 11: Market Shift
Market Shift The market has already begun the shift from surgery to stents (procedures and revenue opportunity) 30,000 $210M 2024 30,000 $80M 95,000 40,000 $280M 2027 40,000 $110M 75,000 60,000 $420M 2030 60,000 $160M 45,000 CAS TCAR CEA 11
Slide 12: The CGuard Difference: The Impact of MicroNet Technology
The CGuard® Difference: The Impact of MicroNetTM Technology1 Approximately 2/3 of neurovascular events (stroke, TIA) occur after carotid interventions take place 2. Prevention depends on the protection from the stent implanted VS. MicroNet : Advanced Protection Technology MicroNet captures and locks
Slide 13: Stent Cell Sizes (Mechanism of Action)
Stent Cell Sizes (Mechanism of Action) Area Comparison (mm2) CGuard® RoadSaverTM *165µ 375µ 500µ 1050µ 1900µ Closed cell stent Open cell stent ACCULINK WallStent * Bench test results may not necessarily be indicative of clinical performance. Stent images approximately at scale but not exact * Averag
Slide 14: Long-Term Stent Performance is the Cornerstone of Our Business
Long-Term Stent Performance is the Cornerstone of Our Business Benefits are independent of access method We are positioned to CGuard Prime CAS Tandem capitalize on the ongoing Stroke Transfemoral/ paradigm shift toward a Transradial “stent first” approach and away from surgery CGuard® Prime Tandem T
Slide 15: Scientific Advisory Board (Multidisciplinary KOLs)
Scientific Advisory Board (Multidisciplinary KOLs) Sean Lyden, M.D. Chris Metzger, M.D. Kenneth Rosenfield, M.D. Adnan H. Siddiqui, M.D., Ph.D. Vascular Surgeon Interventional Cardiologist, Interventional Cardiologist Professor, Vice Chairman of System Vascular Chief the Department of Neurosurgery 1
Slide 16: Unmatched Foundational Data and Evidence
Unmatched Foundational Data and Evidence 16
Slide 17: PMA Trial Design (C-GUARDIANS)
PMA Trial Design (C-GUARDIANS) Prospective, multicenter international single-arm clinical trial Pivotal Study Objective Evaluate the safety and efficacy of the CGuard® Carotid Stent System in the treatment of carotid Primary Endpoints artery stenosis Composite of DSMI through 30 days or ipsilateral
Slide 18: C-GUARDIANS: 30-Day Safety Outcomes
C-GUARDIANS: 30-Day Safety Outcomes 30-Day Death/Stroke/MI (DSMI) rates, compared to other carotid trials CGUARDIANS 30-day outcomes 30-day DSMI (multiple FDA trials) Intention to Treat Per Protocol1,2 8.30% 30-day DSMI 0.95% (3) 0.63% (2) 5.80% 5.40% 5.20% 5.10% 4.80% Death 0.32% (1) 0.0% (0) 3.50%
Slide 19: C-GUARDIANS: 1 Year Outcomes
C-GUARDIANS: 1 Year Outcomes 365-Day Death/Stroke/MI (DSMI) rates, compared to other carotid trials CGUARDIANS 365-day 365-day (multiple FDA trials) Intention to Treat Per Protocol1,2 12.20% 9.60% Primary Endpoint: 30-day 8.90% Death, Stroke, or MI + 1.93% (6) 1.70% (5) Ipsilateral Stroke between 7.
Slide 20: OUS Clinical Data Supporting CGuard Periprocedural Safety
OUS Clinical Data Supporting CGuard® Periprocedural Safety CGuard commercially available in Europe since 2015 (CE Mark) Study Year N DS 30-Day % (n) DSMI 30-Day % (n) CARENET 2015 30 0.0%(0) 0.0%(0) PARADIGM 2016 101 0.0%(0) 0.0%(0) CASANA 2017 82 1.22%(1) 1.22%(1) WISSGOTT I 2017 30 0.0%(0) 0.0%(0)
Slide 21: CARMEN Meta-Analysis (112 Studies, 68K Patients)
CARMEN Meta-Analysis (112 Studies, 68K Patients)1 30-day and 12-month event rates by stent type (random-effect model) Terumo Gore Event FGS SGS RoadSaver/ (not marketed) CGuard • Improvements from second- Casper generation stents (SGS) 30-day Stroke [%] 3.01 0.60 0.50 2.89 0.54 relative to first-gen
Slide 22: TCAR
TCAR INSPIREMO
Slide 23: Transcarotid Arterial Revascularization (TCAR): Direct Carotid Access with Reverse Flow
Transcarotid Arterial Revascularization (TCAR)1: Direct Carotid Access with Reverse Flow InspireMD Combines SwitchGuard NPS2 with Best-in-Class CGuard® Implant 1. Transient flow reversal combined with sustained embolic prevention in transcervical revascularization of symptomatic and highly-emboligen
Slide 24: Developing Comprehensive TCAR Solution
Developing Comprehensive TCAR Solution 80cm TCAR Market Opportunity ~3,000 TCAR-trained physicians in the U.S.1 ~30,000 TCAR procedures (~$210M) performed in the U.S. in 2024, double-digit growth projected1,2 1 Piper-Sandler model, 05/01/24 2 Piper-Sandler model, 05/01/24 24
Slide 25: Commercial and Corporate
Commercial and Corporate INSPIREMO
Slide 26: Roadmap / Milestones
Roadmap / Milestones Key Value Drivers 2025 2026 2027 CGuard® Prime CAS Approval CGuard Prime CAS Market Expansion Further Commercial Expansion in the U.S. Launch for CAS CGuard Prime TCAR Approval Potential Global Expansion (Asia) U.S Operational Expansion CGuard Prime indicated stent for TCAR Buil
Slide 27: Commercial Footprint
• Active selling in more than 30 countries Commercial Footprint • Over 63,000 systems sold • Average CAS Market share of 25% Signed agreement with Chinese distributor. Working toward distribution Investigational Device Exemption (IDE) trial enrollment completed Q2 Exploring expansion 2023; PMA appro
Slide 28: Robust Intellectual Property Portfolio
Robust Intellectual Property Portfolio Proprietary platform technology supported by IP Patent Rights Issued Pending USA 20 7 Rest of World 54 21 InspireMD will continue to strengthen and broaden its patent protection globally to enable future pipeline products IP Counsel: Kligler and Associates, P.A
Slide 29: Transformational May 2023 Financing Up To $113.6 Million
Transformational May 2023 Financing Up To $113.6 Million To advance the company towards potential US approval and launch of CGuard® EPS and other value-creating milestones $42.2 million upfront funding Strong validation from leading fundamental healthcare investors, with $71.4 million tied to the ac
Slide 30: Summary Financials
Summary Financials June 23, 2025 NASDAQ Capital Markets NSPR Stock Price $2.52 Average 3 Month Volume 48.9K Shares Outstanding 30.7M Shares Outstanding with Prefunded Warrants 55.4M Market Capitalization with Prefunded Warrants $139.6M Cash Balance - March 31, 2025 $26.1M Debt $0M 30
Slide 31: NASDAQ Nasdaq: = NSPR NSPR
NASDAQ Nasdaq: =NSPR NSPR